As an aging population grapples with an ever-changing pharmaceutical landscape, the issue of pill color and shape becomes a critical concern. The author, a 73-year-old individual, highlights the inconvenience and potential dangers of medication changes, particularly those involving color and shape. This personal narrative underscores a broader issue: the lack of standardization in generic drug appearance, which can lead to confusion and potentially serious health consequences.
The author's daily routine involves meticulously organizing and taking six medications, a task made more challenging by the frequent changes in pill appearance. This situation is not unique; the Civic Science data center reports that nearly 70% of Americans take at least one over-the-counter drug regularly, and the average American adult takes two or more prescription drugs daily. With such widespread reliance on medication, the impact of color and shape changes becomes even more significant.
The primary reason for these changes lies in patent laws, which require generic drug manufacturers to differentiate their products from brand-name medications. This differentiation often involves altering the shape, color, and size of the pills. Pharmacies also contribute to this confusion by rotating among different generic suppliers, each with its own imprint on the medication's appearance. As a result, patients may encounter pills with different colors, sizes, and shapes, even for the same medication.
The consequences of these changes are alarming. A 2014 study published in Annals of Internal Medicine found that a 34% likelihood of patients discontinuing their medication after a color change, and this likelihood increased to 66% with a shape change. More recent research by doctors Darrick Lee and Erin M. Noren further underscores the issue, with patients discontinuing their medication due to changes in color and shape. These findings highlight the potential for serious health consequences when patients are confused about their medication.
The Food and Drug Administration (FDA) does not mandate coordination between pharmaceutical companies or prohibit changes to cosmetic formulas. This lack of regulation allows companies to make changes without prior notice to patients. Insurance companies can also dictate supplier switches, further complicating the situation. As the population ages, the responsibility of monitoring medication changes falls increasingly on individuals, particularly those with diminished eyesight and cognitive abilities.
To address this issue, patients can take steps such as ordering pill packs or blister packs, which provide a more organized and visible way to manage medications. Online resources, like pill identifier tools, can help patients identify medications based on color and shape, but these should not replace professional advice from pharmacists or doctors. Additionally, patients can request that doctors write 'dispense as written' on prescriptions to avoid generic versions, although this may increase costs.
However, the onus should not solely be on individual patients. The FDA should issue guidance to drug manufacturers to regularize the size and shape of generic pills, ensuring consistency and reducing confusion. This is especially crucial for older individuals who may struggle with visual and cognitive changes.
In conclusion, the issue of pill color and shape changes is a significant concern for an aging population. Standardization and better communication between pharmaceutical companies, pharmacies, and patients are essential to mitigate the potential dangers and ensure the safe and effective use of medications. As the author's story illustrates, the impact of these changes extends beyond mere inconvenience, affecting the health and well-being of millions.
